ArticleTrials2022

Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.

Katharina A Mayer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.